XML 333 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue recognition (Tables)
3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue The Company's revenues disaggregated by operating segment and major sources for the three months ended March 31, 2024 and 2023 were as follows:
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
USGNon-USG TotalUSGNon-USG Total
Commercial Product sales$0.3 $118.2 $118.5 $— $106.2 $106.2 
MCM Product sales114.1 41.3 155.4 26.1 11.1 37.2 
Bioservices:
Services— 18.3 18.3 — 12.6 12.6 
Leases— 0.2 0.2 — 1.8 1.8 
Total Bioservices$— $18.5 $18.5 $— $14.4 $14.4 
Contracts and grants7.4 0.6 8.0 4.9 1.6 6.5 
Total revenues$121.8 $178.6 $300.4 $31.0 $133.3 $164.3 
Schedule of Rollforward of Contract Liabilities The following table presents the roll forward of the contract liability balances:
Contract Liabilities
Balance at December 31, 2023$29.9 
Balance at March 31, 2024$9.7 
Revenue recognized in the period from amounts included in contract liability at the beginning of the period:$24.0 
Schedule of Accounts Receivable, Net
Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:
March 31, 2024December 31, 2023
Accounts receivable:
Billed$194.1 $141.8 
Unbilled41.6 51.4 
Allowance for expected credit losses(2.2)(2.2)
Accounts receivable, net$233.5 $191.0